KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

CRISPR Therapeutics AG (CRSP) EBT: 2014-2024

Historic EBT for CRISPR Therapeutics AG (CRSP) over the last 11 years, with Dec 2024 value amounting to -$403.9 million.

  • CRISPR Therapeutics AG's EBT fell 24.40% to -$105.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$525.8 million, marking a year-over-year decrease of 97.06%. This contributed to the annual value of -$403.9 million for FY2024, which is 123.05% down from last year.
  • Latest data reveals that CRISPR Therapeutics AG reported EBT of -$403.9 million as of FY2024, which was down 123.05% from -$181.1 million recorded in FY2023.
  • CRISPR Therapeutics AG's 5-year EBT high stood at $379.5 million for FY2021, and its period low was -$651.8 million during FY2022.
  • In the last 3 years, CRISPR Therapeutics AG's EBT had a median value of -$403.9 million in 2024 and averaged -$412.3 million.
  • Its EBT has fluctuated over the past 5 years, first slumped by 628.46% in 2020, then skyrocketed by 206.70% in 2021.
  • Over the past 5 years, CRISPR Therapeutics AG's EBT (Yearly) stood at -$355.7 million in 2020, then surged by 206.70% to $379.5 million in 2021, then crashed by 271.74% to -$651.8 million in 2022, then surged by 72.22% to -$181.1 million in 2023, then plummeted by 123.05% to -$403.9 million in 2024.